PPT1 and Intellectual disability: The phenotypic spectrum is highly variable in CLN1 (PPT1) and CLN6 diseases and application of targeted next generation sequencing panels for seizures, intellectual disability or retinopathy, or whole exome sequencing will likely identify more patients with nonclassical NCL phenotypes.